期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 107, 期 1, 页码 129-135出版社
WILEY
DOI: 10.1002/cpt.1679
关键词
-
资金
- Gerber Foundation
- Ohio Development Services Agency
- Ohio Third Frontier [TECG20170361]
- Cincinnati Children's Hospital Medical Center's Innovation Fund
- State of Ohio
Imagine it is 2030, and the drug label is in the cloud, is interactive, and can provide model-informed precision dosing support based on an individual's genomic and physiologic makeup that is uploaded via a user-friendly interface. Precision medicine has vastly improved our ability to provide tailored therapeutics, and groundbreaking advances in noninvasive systems have generated smart wearable devices that can follow our physiologic state and drug exposure in real time. One device consists of a microfluidic drug biosensor with a transmitter attached to the skin and a mobile app that displays concentration values and trends while issuing alerts and providing suggestions on dose changes when out of range. This sounds compelling, but why has model-informed precision dosing not yet become common clinical reality in 2020?
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据